Hill Rom (US) is one of the leading players in Spirometers Market

The spirometers market is expected to reach USD 1,047 million by 2023 from USD 655 million in 2018, at a CAGR of 9.8%. Market growth is largely driven by the rising global incidence of respiratory diseases, global population, and technological advancements in spirometer devices. Opportunities for growth of the market exist in emerging economies on account of increasing pollution levels and rising awareness regarding COPD and other respiratory conditions. On the other hand, the time required to carry out tests using spirometers and data accuracy issues associated with personalized spirometers are expected to limit market growth during the forecast period.

The spirometers market is highly consolidated in nature, with a few players offering a variety of products. The major players operating in this market are Hill Rom (US), Vyaire Medical (US), Fukuda Sangyo (Japan), Chest MI (Japan), Schiller AG (Switzerland), MGC Diagnostics (US), Medical International Research (Italy), NDD Medical Technologies (Switzerland), Vitalograph (UK), and MidMark Corporation (US).

The key strategies followed by most companies in the spirometers market are product launches and partnerships. These two strategies accounted for the largest share of the overall growth strategies mapped from 2015 to 2018.

Hill-Rom is the largest player in the spirometers market. The company focuses on the development of devices, consumables, accessories, and software required to perform spirometer tests. These products are sold under the brand Welch Allyn. The company also invests a significant amount on research and development activities. In 2018, it spent ~5% of its revenue on R&D activities. The company has a global presence through its own subsidiaries as well as a network of distributors. Hill Rom has become a key player in the spirometers market after its acquisition of Welch Allyn.

Coronary Stent Market – Hospitals form the fastest growing end user segment

The coronary stent market is expected to reach USD 10.31 billion by 2021 from USD 7.16 billion in 2016, at a CAGR of 7.6% from 2016 to 2021. The market is mainly driven by factors such as technological advancements, increasing number of percutaneous coronary intervention (PCI) procedures, rising burden of CAD, increasing demand for minimally invasive procedures, and rising geriatric population.

A coronary stent is a small, expandable tube-shaped device placed in the coronary arteries that supply blood to the heart. Coronary stents are used in percutaneous coronary intervention (PCI) procedures to treat patients with coronary artery disease (CAD). They are used for a wide range of indications in CAD, including de novo lesions, small-vessel disease (SVD), bifurcation lesions, and tortuous and narrow lesions.

Hospitals

This segment includes both government and private hospitals that provide treatment to the patients with CAD. The market for this segment is mainly driven by the rising patient pool, growing number of PCI procedures in hospitals, improving healthcare infrastructure, and favorable reimbursement scenario in developed and developing countries. In addition, major players in the coronary stents market are adopting various strategies to enhance the utilization of stents in hospitals.

Global Perfusion Systems Market - Major Growth Strategies Adopted by Key Players

The global perfusion systems market is segmented on the basis of type and region. By type, the market is segmented into cardiopulmonary perfusion systems, cell perfusion systems, and ex vivo organ perfusion systems. The perfusion systems market is projected to reach USD 1,198.8 million by 2021 from USD 989.4 million in 2016, at a CAGR of 3.9% from 2016 to 2021.

This market is highly fragmented with different key players for the different types of perfusion systems. The major players in the cardiopulmonary perfusion systems market include Getinge AB (Sweden), Medtronic plc (Ireland), LivaNova PLC (U.K.), Terumo Corporation (Japan), and XENIOS AG (Germany). The major players in the ex vivo organ perfusion systems market are Lifeline Scientific, Inc. (U.S.) and XVIVO Perfusion AB (Sweden), while, Repligen Corporation (U.S.), Spectrum Laboratories, Inc. (U.S.), Merck KGaA (Germany), Harvard Bioscience, Inc. (U.S.), and ALA Scientific Instruments, Inc. (U.S.) are some of the leading players in the cell perfusion systems market.

Key players adopted strategies such as partnerships, collaborations, joint ventures, agreements, mergers & acquisitions, approvals, product launches, and expansions to maintain and enhance their position in the market.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164273069

Partnerships, collaborations, joint ventures, agreements, and mergers & acquisitions accounted for 28.6% of the all strategic developments from 2013 to 2016. Players adopted this strategy to strengthen their distribution networks, expand their research network, and enhance their market reach & customer base. In 2015, Getinge AB partnered with iMDsoft GmbH to integrate its data management systems into Getting’s heart-lung machines, blood/gas monitors, and heater-cooler units. Similarly, in 2015, Sorin and Cyberonic merged to form LivaNova PLC. The key players that adopted these strategies were Getinge AB, Medtronic plc, LivaNova PLC, Terumo Corporation, and XENIOS AG.

Product launches accounted for 21.9% of strategic developments in the market from 2013 to 2016. This strategy was employed by players to enhance their product portfolios. In 2015, Medtronic plc launched Affinity CP Centrifugal Blood Pump in Brazil. Similarly, LivaNova PLC launched Flextherm— heating and cooling systems in 2015. In 2016, Terumo Corporation launched the CAPIOX FX Advance oxygenator. Medtronic plc, LivaNova PLC, Lifeline Scientific, Inc., XVIVO Perfusion AB, Repligen Corporation, and Terumo Corporation were the key players who adopted this strategy.

Sample of the Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=164273069 
Approvals accounted for 16.2% of total strategic developments in the perfusion systems market from 2013 to 2016. This strategy was adopted by players to strengthen their product offerings and widen their product distribution network. In 2014, XENIOS received the CE approval for its MiniLung Petite Membrane Ventilator, MiniLung Membrane Ventilator, and iLA Membrane Ventilator. Similarly, in 2015, Lifeline Scientific received the Chinese Food and Drug Administration (CFDA) approval for its LifePort Kidney Transporter device. In 2015, XVIVO received approval for the clinical use of XPS in Canada. The key players that adopted this strategy were XENIOS AG, Lifeline Scientific, Inc., and XVIVO Perfusion AB.

Expansions accounted for 12.4% of key growth strategies adopted by players in the market from 2013 to 2017. This strategy was used by key players to strengthen their distribution networks, increase their global presence, and cater to the needs of their growing customer base. For instance, Lifeline Scientific opened a new facility in Brazil in 2015, to expand its geographic reach. Similarly, in 2017, Terumo opened a new branch for its operations in Myanmar. XENIOS AG, Medtronic plc, Terumo Corporation, MicroPort Scientific Corporation, and Lifeline Scientific, Inc. are the key players that adopted this strategy.

Other strategies such as rebranding, website launch, product deployment, and market development accounted for 21.0% of the total developments. The key players that adopted these strategies were Terumo Corporation, LivaNova PLC, XENIOS AG, and Lifeline Scientific, Inc.

Oral Care Market Dynamics and Major Market Developments

According to research report oral care market is expected to grow from USD 41.56 billion in 2017 to USD 53.97 billion by 2023, at a CAGR of 4.5% from 2017 to 2022. Oral care products are used for the diagnosis, treatment, and prevention of dental diseases; maintenance of oral hygiene; or postoperative care. These products include toothbrushes, toothpastes, mouthwashes/rinses, denture products, dental accessories/ancillaries, and dental prosthetic cleaning solutions. The base year considered for the study is 2016, and the forecast has been provided for the period between 2017 and 2022.

Market Dynamics

Drivers

• Growing awareness on oral hygiene
• Technological advancements in oral care products
• Rising incidence of dental caries and other periodontal diseases

Restraints

• Competitive pricing pressure faced by prominent players

Opportunities

• Untapped emerging markets
• Increasing online purchase of oral care products

Challenges

• High dependence on retail stores

Key players considered in the analysis of the oral care market are Colgate-Palmolive Company (US), The Procter & Gamble Company (US), Unilever plc (UK), Koninklijke Philips N.V. (Netherlands), GlaxoSmithKline plc (UK), Johnson & Johnson (US), GC Corporation (Japan), Dr. Fresh, LLC (US), 3M Company (US), Young Innovation Inc. (US), Ultradent Products, Inc. (US), Lion Corporation (Japan), Henkel AG & Company, KGaA (Germany), Sunstar (Japan), and Kao Corporation (Japan).

Major Market Developments

• In August 2016, Colgate-Palmolive Company (US) launched the Cibaca Vedshakti toothpaste in India. This product costs INR 50 (USD 0.78) for 175 grams, which is around 30% cheaper than the Dant Kanti toothpaste, a product from Patanjali Ayurved Ltd. (a prominent local player in India).
• In 2016, Koninklijke Philips N.V. (Netherlands) introduced Sonicare FlexCare Platinum Connected electric toothbrush. This electric toothbrush is rechargeable and feature inbuilt ultrasonic technology, which aids the safe and effective removal of dental plaque and reduces the chances of gingival inflammation and bleeding.

Technological innovation in oral care products drives the growth of the oral care market.

Product innovation has enabled the development of technologically advanced and easy-to-use oral care products such as electrical toothbrushes and vibrators. Players such as The Procter & Gamble Company (US) and Koninklijke Philips N.V. (Netherlands) are increasingly focusing on innovation in the market. These players are focusing on the development of application-based toothbrushes and smart electric toothbrushes, which are connected to a smartphone with the Bluetooth technology.  Recently, some major players launched interactive toothbrushes equipped with position detection and motion sensor technologies. These toothbrushes screen the oral cavity to provide a real-time guidance for brushing and maintaining oral health. The development of such innovative products enables users to track oral care habits and improve oral health. Owing to these advantages, end users are willing to spend more on advanced products; this, in turn, is expected to drive the growth of the market in the coming years.

Cancer Biomarkers Market Dynamics and Global Forecast to 2022

The global cancer biomarkers market is accounted for USD 10.31 billion in 2016 and is expected to grow at a CAGR of 12.2% to USD 20.48 billion by 2022 during the forecast period. Cancer biomarkers are substances or processes that are indicative of the presence of cancers in the human body. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. They can be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. They enhance cancer detection and facilitate high-speed noninvasive diagnosis using genomics and proteomics.

Pharmaceutical and biotech companies are increasingly focusing on the use of biomarkers in their drug discovery and development process and have formed strategic alliances for sharing technology for biomarker applications in large-stage clinical trials are fueling the growth of this market. The base year considered for the study is 2016, and the forecast has been provided for the period between 2017 and 2022.

Cancer biomarkers Market Dynamics

Drivers

• Technological advancements
• Rising incidence of cancer
• Enhanced accuracy and speed of diagnosis
• Increasing use of cancer biomarkers in drug discovery and development
• Increasing research on cancer biomarkers

Restraint

• Poorly suited regulatory and reimbursement systems
• High capital investment and low benefit-cost ratio
• Technical issues related to sample collection and storage

Opportunities

• Personalized medicine
• Companion diagnostics
• Emerging economies

Challenges

• Proving clinical validity and utility of biomarker-based tests leading to their insufficient acceptance

Artificial Tendons and Ligaments Market Top Players and Strategies

The global artificial tendons and ligaments market is projected to reach USD 35.0 million by 2023 from USD 18.5 million in 2018, at a CAGR of 13.6%. The artificial tendons and ligaments market is emerging and fragmented in nature with various regional and international players. In 2017, the artificial tendons and ligaments market was dominated by LARS (France) and Neoligaments (UK).

LARS held the leading position of the global artificial tendons and ligaments market in 2017. The company offers the Ligament Augmentation Reinforcement System (LARS) for a wide range of applications, such as soft-tissue repair and reconstruction for the treatment of knee, shoulder and arm, foot and ankle, and hip injuries. Since 1992, more than 60,000 LARS ligaments have been implanted by 400 surgeons worldwide, with more than 30,000 used for ACL alone. LARS ligaments have been successfully used for more than 25 years in a wide variety of patients ranging from the general public to elite athletes. LARS ligament procedures have led to high patient satisfaction, shortened recovery time, early return to normal activity (within 3–6 months), immediate restoration of stability and function, and minimal complications. Also, these procedures are associated with a high implant survival rate of 92.9% after more than ten years of ACL reconstruction. The company’s operations are spread across Australia, the UK, France, Germany, and Canada owing to its distribution agreement with the Corin Group (UK) and Revolution Surgical (Australia). Complications associated with older-generation products and high failure rates have adversely affected the brand image of artificial tendons and ligaments. In order to address these concerns and increase its customer base, LARS focuses on publishing research papers showcasing the efficacy of its products. For instance, the company has published 22 papers regarding the use of LARS in knee ligament reconstruction of the ACL and PCL.

Weight Loss and Weight Management Market – Attractive Opportunities and Global Forecast 2022

Globally, the number of people suffering from obesity has increased significantly over the years. Unhealthy eating habits and sedentary lifestyles are the major factors responsible for the rising obesity rates across the globe. Governments across the globe have identified the immediate need to improve the health and well-being of the population and are taking necessary steps to increase the awareness for the same. In addition to favourable government initiatives, the awareness about health and well-being has increased among the population in several countries, and people are increasingly focusing on leading a healthy lifestyle. These factors are creating a favorable environment for the greater uptake of weight loss and weight management products and services across the globe.

According to research report the weight loss and weight management market is expected to reach USD 245.51 billion by 2022 from USD 165.81 billion in 2016, at a CAGR of 6.9% from 2017 to 2022.

Major Market Developments

• In 2017, Conyers Park and Atkins combined to form a new holding company, The Simply Good Foods Company. This company is expected to expand its platform through investment opportunities in the snacking space and broader food category.
• In 2017, Brunswick partnered with VirZOOM To launch the VirZOOM solution, which is expected to transform Life Fitness’s Discover SE3 bikes into a virtual reality experience.
• In 2016, Brunswick acquired Indoor Cycling Group (ICG). The acquisition expanded Brunswick’s portfolio of fitness products.
• In 2016, Atkins partnered with Chef’d to launch a low carb meal solution for health-conscious consumers

Clinical Microbiology Market by Application - Global Forecast to 2023

According to research report clinical microbiology market is expected to reach USD 4.95 billion by 2023 from USD 3.42 billion in 2017, at a CAGR of 6.4% during the forecast period.

This research study involves the extensive use of secondary sources, directories, and databases (such as World Health Organization, Food and Drug Administration, The World Bank, Organisation for Economic Co-operation and Development (OECD), and the American Society of Microbiology), to identify and collect information useful for this technical, market-oriented, and financial study of the clinical microbiology market. In-depth interviews were conducted with various primary respondents, including subject-matter experts (SMEs), C-level executives of key market players, and industry consultants to obtain and verify qualitative and quantitative information and to assess market prospects.

As of 2017, bioMérieux SA (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Abbott Laboratories (US), held the leading position in the global clinical microbiology market. These companies adopted product launches and enhancements; acquisitions; partnerships and collaborations; and expansions as their key growth strategies in the past four years. Some of the prominent players operating in the global clinical microbiology market include Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Bruker Corporation (US), Hologic, Inc. (US), among others.

Stakeholders

• Manufacturers of microbiological testing/clinical microbiology products
• Healthcare service providers
• Manufacturers of pharmaceutical products
• Clinical research organizations (CROs)
• Clinical Testing laboratories
• Food and Beverages Manufacturing Companies
• Manufacturers of petrochemical and biofuel products
• Oil & gas production and distribution companies
• Gas operators, distributors, and regulators
• Environmental monitoring committees
• Manufacturers of environmental monitoring products
• National & regional pollution control boards and organizations
• Research laboratories and academic institutes
• Market research and consulting firm

Scope of the Report

This report categorizes the global microbiology testing/clinical microbiology market into the following segments and subsegments:

Global Microbiology Testing Market, by Application

• Pharmaceutical Applications
• Clinical Applications
• Food Testing Applications
• Energy Applications
• Chemical and Material Manufacturing Applications
• Environmental Applications

 

Veterinary Dental Equipment Market By Product and Animal Type Global Forecast 2023

The veterinary dental equipment market is projected to reach USD 490 million by 2023 from USD 329 million in 2018, at a CAGR of 8.3% during the forecast period. Growth in the global companion animal population, rising incidence of veterinary dental problems, and growth in the number of veterinary practitioners and income levels in developed economies during the forecast period are the primary drivers for the veterinary dental equipment market during the forecast period.

Dental equipment segment to account for the largest share of the veterinary dental equipment market, by product, in 2018

On the basis of product, the dental equipment segment is expected to account for the largest market share in 2018. The large share of this segment can be attributed to the high cost of dental equipment and the rising income level of veterinarians, resulting in the higher adoption of dental equipment.

Small companion animals to hold the largest share of the veterinary dental equipment market, by animal type, in 2018

Based on animal type, the veterinary dental equipment market is categorized into small companion animals and large animals. The small companion animals segment is expected to account for the largest market share in 2018. The large share of this segment can be attributed to the growing companion animal population, increasing pet care expenditure, and the high prevalence of dental diseases in companion animals.

Rising Prevalence of Cancer Driving the Growth of Biopsy Devices Market

According to the new market research report Biopsy Devices Market by Product (Core Needle Biopsy, Aspiration Biopsy, Vacuum Assisted Biopsy) Application (Breast Biopsy, Lung Biopsy, Prostate Biopsy) Guidance (Stereotactic, Ultrasound) & by End User (Hospital) – Global Forecast to 2022″, published by MarketsandMarkets™, the market is expected to reach USD 2.42 Billion by 2022 from an estimated USD 1.74 Billion in 2017, at a CAGR of 6.8% during the forecast period.

Factors such as rising prevalence of cancer, increasing preference for minimally invasive surgeries, and initiatives undertaken by governments & global health organizations are the major factors driving the growth of this market.

By product, the needle-based biopsy instruments segment accounted for the largest share of the market

On the basis of product, the needle-based biopsy instruments segment accounted for the largest share of the global biopsy devices market in 2016. This can be attributed to the preference of needle-based biopsies over open surgical biopsies and increasing preference for minimally invasive surgeries.

The lung biopsy segment is expected to highest growth during the forecast period

Based on application, the lung biopsy segment accounted for the largest share of the biopsy devices market. The growing prevalence of lung cancer will drive market growth. Additionally, the availability of funding for lung cancer research is contributing to the growth of this market segment.

The ultrasound-guided biopsy segment dominated the market in 2016

Based on guidance technique, the ultrasound-guided biopsy segment accounted for the largest share of the biopsy devices market. This quick and simple procedure offers advantages, such as no ionizing radiation exposure, low complication rate, and lower cost as compared to other biopsy techniques.

The hospitals segment held the highest CAGR during the forecast period

Based on end user, the hospitals segment is expected to register the highest growth rate during the forecast period. The strong financial capabilities of hospitals and the presence of trained professionals are the major factors supporting the rising adoption of biopsy devices among hospitals.

North America accounted for the largest share of the biopsy devices market in 2016, followed by Europe. The rising prevalence of cancer, government initiatives to spread awareness about cancer, favorable reimbursement scenario for biopsy devices in the U.S., and the presence of key players in the region are the key factors driving the growth of the biopsy devices market in North America.

The major players in the Biopsy Devices Market are C. R. Bard, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Cook Group Incorporated (U.S.), Devicor Medical Products, Inc., (Leica Biosystems) (Germany), Argon Medical Devices (U.S.), B. Braun Melsungen AG (Germany), Cardinal Health, Inc. (U.S.), Olympus Corporation (Japan), Boston Scientific Corporation (U.S.), FUJIFILM Holdings Corporation (Japan), INRAD, Inc. (U.S.), and Medtronic plc (Ireland).